ReviewClinical kidney journal2023
Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis.Renal failure · 2025Pooled it
- A novel 2D Co-MOF@MnOMikrochimica acta · 2026Article
- Article
- The relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.Renal failure · 2025Article
- Association between the combination of the triglyceride-glucose index and obesity-related indices with hyperuricemia among children and adolescents in China.Lipids in health and disease · 2025Article
- Tanshinone IIA Regulates NRF2/NLRP3 Signal Pathway to Restrain Oxidative Stress and Inflammation in Uric Acid-Induced HK-2 Fibrotic Models.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Association betweenFrontiers in medicine · 2025Article
- Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge.Frontiers in immunology · 2025Review
- Lowering the risk of hyperuricemia and gout is associated with ideal cardiovascular health.Journal of health, population, and nutrition · 2024Article
- Antidiabetic and Antigout Properties of the Ultrasound-Assisted Extraction of Total Biflavonoids fromAntioxidants (Basel, Switzerland) · 2024Article
- Using intravoxel incoherent motion imaging to evaluate uric acid-induced renal injury and efficacy after treatment.The British journal of radiology · 2024Article
- Association of urinary excretion rates of uric acid with biomarkers of kidney injury in patients with advanced chronic kidney disease.PloS one · 2024Article
- The pathogenic mechanism of monosodium urate crystal-induced kidney injury in a rat model.Frontiers in endocrinology · 2024Article
- Increased risk of chronic kidney disease in uric acid stone formers with high neutrophil-to-lymphocyte ratio.Scientific reports · 2023Article
- Association between weight-adjusted-waist index and the risk of hyperuricemia in adults: a population-based investigation.Frontiers in endocrinology · 2023Article
- Assessment of allopurinol use in patients with chronic kidney disease and asymptomatic hyperuricemia: a retrospective cohort study.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asymptomatic hyperuricaemia (HU) is considered a pathogenic factor in multiple disease contexts, but a causative role is only proven for the crystalline form of uric acid in gouty arthritis and urate nephropathy. Epidemiological studies document a robust association of HU with hypertension, cardiovascular disease (CVD) and CKD progression, but CKD-related impaired uric acid (UA) clearance and the use of diuretics that further impair UA clearance likely accounts for these associations. Interpreting the available trial evidence is further complicated by referring to xanthine oxidase inhibitors as urate-lowering treatment, although these drugs inhibit other substrates, so attributing their effects only to HU is problematic. In this review we provide new mechanistic insights into the biological effects of soluble and crystalline UA and discuss clinical evidence on the role of asymptomatic HU in CKD, CVD and sterile inflammation. We identify research areas with gaps in experimental and clinical evidence, specifically on infectious complications that represent the second common cause of death in CKD patients, referred to as secondary immunodeficiency related to kidney disease. In addition, we address potential therapeutic approaches on how and when to treat asymptomatic HU in patients with kidney disease and where further interventional studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.